Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION

v3.10.0.1
STOCK-BASED COMPENSATION
3 Months Ended
Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
STOCK-BASED COMPENSATION
4.
STOCK-BASED COMPENSATION
 
2013 Stock Incentive Plan
 
On June 18, 2013, the Company established the 2013 Stock Incentive Plan (“2013 Plan”). Under the 2013 Plan, during the fiscal year ended September 30, 2018, a maximum number of 22,114,256 shares of the Company’s authorized and available common stock could be issued in the form of options, stock appreciation rights, sales or bonuses of restricted stock, restricted stock units or dividend equivalent rights, and an award may consist of one such security or benefit, or two or more of them in any combination or alternative. The 2013 Plan provides that on the first business day of each fiscal year commencing with fiscal year 2014, the number of shares of our common stock reserved for issuance under the 2013 Plan for all awards except for incentive stock option awards will be subject to increase by an amount equal to the lesser of (A) 3,000,000 Shares, (B) four (4) percent of the number of shares outstanding on the last day of the immediately preceding fiscal year of the Company, or (C) such lesser number of shares as determined by the Company’s Board of Directors (“Board”). The exercise price of each option shall be the fair value as determined in good faith by the Board at the time each option is granted. On October 1, 2018, the aggregate number of authorized shares under the Plan was further increased by 3,000,000 shares to a total of 25,114,256 shares.
 
As of December 31, 2018, a total of 15,669,212 options had been issued to employees and directors and 6,127,500 options had been issued to consultants. The exercise price of each option has either been equal to the closing price of a share of our common stock on the date of grant or has been determined to be in compliance with Internal Revenue Section 409A.
 
Share-based awards
 
During the three months ended December 31, 2018, the Company granted 100,000 options to employees and directors, and 100,000 options to consultants, to purchase shares of common stock under the 2013 Plan
.
 
The Company recognizes compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period, with the exception of options granted subject to a consulting agreement, whereby the option vesting period and the service period are defined pursuant to the terms of the consulting agreement. Share-based compensation expense for awards granted during the three months ended December 31, 2018 was based on the fair market value at period end or grant date fair value estimated using the Black-Scholes Option Pricing Model. The following assumptions were used to calculate the fair value of share based compensation for the three months ended December 31, 2018; expected volatility, 93.15% - 119.44%, risk-free interest rate, 1.38% - 3.23%, expected forfeiture rate, 0%, expected dividend yield, 0%, expected term, 5.75 years. Expected price volatility is the measure by which the Company’s stock price is expected to fluctuate during the expected term of an option. The Company exited shell company status on June 26, 2013. In situations where a newly public entity has limited historical data on the price of its publicly traded shares and no other traded financial instruments, authoritative guidance is provided on estimating this assumption by basing its expected volatility on the historical, expected, or implied volatility of similar entities whose share option prices are publicly available. In making the determination as to similarity, the guidance recommends the consideration of industry, stage of life cycle, size and financial leverage of such other entities. Prior to January 1, 2018, the Company’s expected volatility is derived from the historical daily change in the market price of its common stock since it exited shell company status, as well as the historical daily change in the market price for the peer groups as determined by the Company. Effective January 1, 2018, the Company’s expected volatility is derived from the historical daily change in the market price of its common stock since it exited shell company status.
 
For so called “plain vanilla” options granted to employees, the expected term of the options is based upon the simplified method as defined in ASC 718-10-S99 which averages an award’s weighted-average vesting period and the contractual term for share options. The Company will continue to use the simplified method until it has the historical data necessary to provide a reasonable estimate of expected life in accordance with ASC Topic 718. The Company’s estimation of the expected term for stock options not subject to the simplified method is based upon the contractual term of the option award. For the purposes of estimating the fair value of stock option awards, the risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield. The Company has never paid any dividends on its common stock and does not anticipate paying dividends on its common stock in the foreseeable future.
 
Stock-based compensation expense recognized in the Company’s consolidated statements of operations is based on awards ultimately expected to vest, reduced for estimated forfeitures. Authoritative guidance requires forfeitures to be estimated at the time of grant, and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Since the Company has a limited history of occurrences of stock option forfeitures and a small number of employees it continues to estimate the forfeiture rate of its outstanding stock options as zero, but will continually evaluate its historical data as a basis for determining expected forfeitures.
 
Common Stock Options
 
Stock compensation activity under the 2013 Plan for the three months ended December 31, 2018 follows:
 
 
 
Option

Shares

Outstanding
 
 
Weighted

Average

Exercise

Price
 
 
Weighted

Average

Remaining

Contractual

Term (years)
 
 
Aggregate

Intrinsic

Value
 
Outstanding at September 30, 2018
 
 
15,684,210
 
 
$
0.40
 
 
 
3.89
 
 
$
1,142,521
 
Awarded
 
 
200,000
 
 
$
0.39
 
 
 
-
 
 
 
-
 
Exercised
 
 
(1,525,000
)
 
$
0.37
 
 
 
-
 
 
 
-
 
Forfeited/Cancelled
 
 
(104,212
)
 
$
0.37
 
 
 
-
 
 
 
-
 
Outstanding at December 31, 2018
 
 
14,254,998
 
 
$
0.40
 
 
 
3.75
 
 
$
2,237,885
 
Exercisable at December 31, 2018
 
 
11,720,960
 
 
$
0.38
 
 
 
4.14
 
 
$
2,040,184
 
Vested and expected to vest at December 31, 2018
 
 
14,254,998
 
 
$
0.40
 
 
 
3.75
 
 
$
2,237,885
 
 
As of December 31, 2018, 5,743,356 shares are available for future grants under the 2013 Plan. Share-based compensation expense recorded in the Company’s Consolidated Statements of Operations for the three months ended December 31, 2018 and 2017 resulting from stock options awarded to the Company’s employees, directors and consultants was approximately $339,000 and $193,000, respectively. Of this amount during the three months ended December 31, 2018 and 2017, $66,000 and $62,000, respectively, was recorded to research and development expenses, and $273,000 and $131,000, respectively was recorded in general and administrative expenses in the Company’s Consolidated Statements of Operations.
 
During the three months ended December 31, 2018, 87,567 stock options awarded under the 2013 Stock Incentive Plan were exercised for cash resulting in proceeds to the Company of $32,400. During the three months ended December 31, 2018, 1,437,433 stock options awarded under the 2013 Stock Incentive Plan were exercised on a cashless basis for an aggregate issuance of 477,269 shares of the Company’s Common Stock.
 
As of December 31, 2018, there is approximately $540,000 of unrecognized compensation expense related to unvested stock-based compensation arrangements granted under the 2013 Plan. That cost is expected to be recognized over a weighted average period of 1.32 years.
 
Restricted Stock
 
On February 3, 2017, the Company awarded 1,750,000 shares of Restricted Stock to members of the Board of Directors and management. The shares subject to this grant are awarded under the 2013 Plan and 100% shall fully vest on the second anniversary of the date of grant. In addition, in the event of a Change of Control (as such term is defined in the 2013 Plan), 100% of the grants will immediately vest.
 
On July 19, 2018, the Company awarded 745,000 shares of Restricted Stock to members of the Board of Directors and management and 220,000 shares of Restricted Stock to Dr. Dhillon in his capacity as a consultant. The shares subject to this grant are awarded under the 2013 Plan and 100% shall fully vest on the second anniversary of the date of grant. In addition, in the event of a Change of Control (as such term is defined in the 2013 Plan), 100% of the grants will immediately vest.
 
On September 5, 2018, the Company awarded 100,000 shares of Restricted Stock to a consultant. The shares subject to this grant are awarded under the 2013 Plan and 50,000 vest 90 days from the date of the award and 50,000 vest 365 days from the date of the award. In addition, in the event of a Change of Control (as such term is defined in the 2013 Plan), 100% of the grants will immediately vest.
 
 
Restricted stock activity under the 2013 Plan for the three months ended December 31, 2018 and 2017 follows:
 
 
 
2018
 
 
2017
 
Non Vested at September 30, 2018 and 2017
 
 
2,815,000
 
 
 
1,750,000
 
Awarded
 
 
-
 
 
 
-
 
Vested
 
 
(50,000
)
 
 
-
 
Forfeited
 
 
-
 
 
 
-
 
Non Vested at December 31, 2018 and 2017
 
 
2,765,000
 
 
 
1,750,000
 
 
The weighted average restricted stock award date fair value information for the three months ended December 31, 2018 and 2017 follows:
 
 
 
2018
 
 
2017
 
Non Vested at September 30, 2018 and 2017
 
$
0.57
 
 
$
0.39
 
Awarded
 
 
-
 
 
 
-
 
Vested
 
 
(0.43
)
 
 
-
 
Forfeited
 
 
-
 
 
 
-
 
Non Vested at December 31, 2018 and 2017
 
$
0.57
 
 
$
0.39
 
 
Non-employee restricted shares subject to vesting are revalued at each vesting date and at the end of the reporting period, with all changes in fair value recorded as stock-based compensation expense. For the three months ended December 31, 2018 and 2017 compensation expense recorded for the restricted stock awards was approximately $205,000 and $143,000, respectively.